Skip to main content
OpenTrials
Completed

NCT Number: NCT05815719

Continuous Double Ovarian Stimulation.

To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fertility Issues Genital Diseases Infertility Urogenital Diseases

Age range

18 year–43 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Instituto Bernabeu

Alicante, 03016, Spain

About this study

The purpose of this pilot study is to evaluate the efficacy of the weekly use of corifollitropin alfa in terms of ovarian stimulation results and its biological outcomes (total number of oocytes retrieved) in case of ovarian stimulation cycles in double stimulation modality (DUOSTIM) and in comparison with the conventional DUOSTIM protocol: daily administration of gonadotropins.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with indication for DUOSTIM protocol
  • Maximum age of 43 years (up to one day before their 44th birthday) at the beginning of the stimulation process.
  • Ability to participate and comply with the study protocol.
  • To have given written consent

Exclusion criteria

  • Finding of ovarian pathology at the time of initiation of stimulation: e.g. ovarian cysts.
  • Concurrent participation in another study.

Treatment and study plan

Corifollitropin alfa

Drug

150 micrograms per dose

Other names: 4 Weekly Corifollitropin Alfa injections

Follitropin alfa

Drug

Variable dose.

Other names: Daily injections of gonadotropins

Follitropin Alfa Biosimilar

Drug

Variable dose.

Other names: Daily injections of gonadotropins

Urinary Human follicle stimulating hormone

Drug

Variable dose.

Other names: Daily injections of gonadotropins

Primary outcomes

  1. Total Number of Retrieved Oocytes

    Time frame: Through study completion, an average of four weeks

    To investigate the total number of oocytes retrieved through ovarian stimulation in double ovarian stimulation cycles (DUOSTIM) utilizing weekly subcutaneous injections of Corifollitropin alfa (study group) vs. daily injections of gonadotropins (control group).

  2. Number of MII Oocytes

    Time frame: Through study completion, an average of four months

    To compare the total number of MII oocytes obtained in double stimulation cycles in study vs control groups

Secondary outcomes

  1. Duration of Ovarian Stimulation

    Time frame: Through study completion, an average of four months

    Total days of follicular and luteal phases

  2. Number of Injections

    Time frame: Through study completion, an average of four months

    Number of injections during the DUOSTIM cycle

Sponsors and collaborators

Lead sponsor

Instituto Bernabeu

Other

Registry information

Official study title

Continuous Ovarian Stimulation in DUOSTIM Cycles.

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 18, 2023
Registry last updated
May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.